Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotic Accelerator From BARDA Nears Investment Stage

This article was originally published in The Pink Sheet Daily

Executive Summary

Federal funding could pay to help early antibiotic discovery efforts with 'fragile' pipeline still struggling.

You may also be interested in...



FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway

FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.

US FDA Likely To Embrace In-Person, Remote Combo For Facility Inspections Going Forward

The system likely will evolve as the post-pandemic world unfolds, but adds to the list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.

US FDA/Industry Thinking PDUFA VIII Could Be A Hybrid Negotiation

Virtual meetings proved successful, and could be allowed again when the next round of user fee reauthorization talks convene.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS079504

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel